Document Detail

Ternary biomolecular nanoparticles for targeting of cancer cells and anti-angiogenesis.
MedLine Citation:
PMID:  20542111     Owner:  NLM     Status:  MEDLINE    
To develop a targeted drug delivery system for cancer therapy and anti-angiogenesis, amphiphilic heparin bioconjugates were synthesized by chemical conjugation of hydrophobic retinoic acid and a targeting ligand, folic acid, to the heparin backbone (HFR). The chemical structure of the HFR conjugates was confirmed by proton nuclear magnetic resonance ((1)H NMR). Various HFR conjugates with different retinoic acid coupling ratios were obtained by modulating the retinoic acid feed molar ratio. The anticoagulant activity of the HFR conjugates decreased to 30% of heparin levels as measured by anti-FXa chromogenic assay. The bioconjugates retained the anti-angiogenic effect, showing a significant decrease in endothelial tubular formation using a Matrigel model. In aqueous solutions, the bioconjugates readily self-assembled to form nanoparticles via the hydrophobic interaction among retinoic acid. The HFR nanoparticles were spherical and ranged from 150 to 300 nm, depending on the degree of retinoic acid coupling. The presence of folic acid efficiently enhanced the cellular uptake of the HFR nanoparticles in folate receptor-positive cells. Furthermore, the internalized HFR nanoparticles demonstrated greater cytotoxicity against folate receptor-positive cells compared to free retinoic acid. These results indicate that specific delivery of retinoic acid with ternary biomolecular nanoparticles targeting folate receptor-positive tumors is a promising strategy to enhance chemotherapy efficacy with minimal side effects.
Il-Kyu Park; Thanh Huyen Tran; In-Hyeok Oh; Yu-Jin Kim; Kwang Jae Cho; Kang Moo Huh; Yong-Kyu Lee
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-11
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  41     ISSN:  1879-0720     ISO Abbreviation:  Eur J Pharm Sci     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  148-55     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 Elsevier B.V. All rights reserved.
Department of Applied Chemistry & Biological Engineering, Chungnam National University, 220, Gung-dong, Yuseng-gu, Daejeon 305-764, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors*
Magnetic Resonance Spectroscopy
Reg. No./Substance:
0/Angiogenesis Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparing techniques for drug loading of shape-memory polymer networks-effect on their functionaliti...
Next Document:  In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the periphera...